African parasite makes component of fat differently from all other organisms

Studying the parasite that causes African sleeping sickness, scientists at Johns Hopkins have discovered a previously unknown way of making fatty acids, a component of fat and the outer layer of all cells. The find unveils more about the biology of this hard-to-kill parasite and could lead to a target for designing new drugs to fight the illness that infects a half-million people and kills 50,000 a year worldwide.

Results of the study, in the Aug. 25 issue of Cell, "show that this is a completely new biochemical pathway for making fatty acids," says Soo Hee Lee, Ph.D., a postdoctoral fellow in the Department of Biological Chemistry at the Institute for Basic Biomedical Sciences at Hopkins. "It may be that the enzymes in the pathway could be good targets for designing drugs to treat sleeping sickness."

The single-celled trypanosome that causes African sleeping sickness, transmitted between humans and animals by bloodsucking tsetse flies, goes through several different stages in its life cycle. One such form is harbored by the insect and the other multiplies in a host's bloodstream.

There, the parasite avoids detection by the human immune system by replacing each of the 10 million proteins on its outer layer - known as the cell membrane - with different proteins that are not recognized by immune cells. These proteins are attached to the cell membrane by an anchor composed in part of a fatty acid only 14 units long - dubbed myristate -- whereas typically, in other organisms, these types of anchors contain longer fatty acids, generally 16 or 18 units long.

"For many years we thought the parasite had to get the myristate from its human host because we never could see any evidence that it could make the fatty acid itself," says Paul Englund, Ph.D., a professor of biological chemistry in the Institute of Basic Biomedical Sciences at Hopkins. "Several years ago we found that it does actually make myristate as well as other fatty acids, and now we found that it uses a biochemical pathway we never knew to look for."

They learned about this new fatty acid-making pathway by hunting the trypanosome genome for stretches of DNA known to be involved in fatty acid synthesis in other organisms, like animals and plants.

The researchers reasoned that knocking out the fatty acid-making genes would prevent the parasite from making myristate and other fatty acids.

But when one member of the research team, Jennifer Stephens, knocked out a single gene in the trypanosome known to make fatty acids in other organisms, there was no change in the parasite's ability to make myristate. Surprised, the researchers then examined the trypanosome genome more carefully and discovered enzymes that in other organisms are known to increase the size of a fatty acid molecule - dubbed elongases, for making fatty acids longer - but never have been shown to actually make a new fatty acid molecule.

Lee knocked out these elongases to see if the parasite might have difficulty making fatty acids. To the researchers' surprise, the parasites lacking elongases were unable to make the 14-unit myristate or other fatty acids.

"A novel feature of the elongase pathway is that it contains four different enzymes that take turns in elongating fatty acids," says Lee. "This modular pathway allows the parasite to control the size of the fatty acids it makes."

"It turns out that trypanosomes use an entirely unique mechanism of making fatty acids. No other organism ever studied uses elongases to make them," says Englund, suggesting that attacking biochemical pathways that make fatty acids could be a way to treat sleeping sickness. According to the researchers, the research community is extremely interested in developing drugs that target bacterial enzymes involved in fatty acid synthesis. An example of one is called isoniazid, which currently is used to treat tuberculosis.

"Trypanosomes cause significant health problems in remote areas of Africa with poor health care," says Englund. "There is tremendous need for new drugs to cure these diseases."

Source: Johns Hopkins Medical Institutions

Related stories:

Plant gene replacement results in the world's only blue rose
Australian and Japanese researchers have demonstrated the application of RNAi technology for gene replacement in plants, developing the world's only blue rose.
Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.
Researchers study how pistachios may improve heart health
Going green may be heart healthy if the green you choose is pistachio nuts, according to researchers at Penn State who conducted the first study to investigate the way pistachios lower cholesterol.
Discovery offers new understanding of diabetes drug target
Scientists at the University of Leicester have published findings about a new advance in the study of major diabetes drug target.
New class of hormone from 'healthy fat cells' benefits body metabolism in mice
(PhysOrg.com) -- Scientists at the Harvard School of Public Health (HSPH) have identified in mice a newly discovered class of hormones -- lipokines. In tomorrow's issue of the journal Cell they report that lipokine is a molecule in mice that helps stop, or even reverses obesity-related conditions such as insulin resistance and "fatty liver."
Hormone discovery points to benefits of 'home grown' fat
A hormone found at higher levels when the body produces its own "home grown" fat comes with considerable metabolic benefits, according to a report in the September 19th issue of the journal Cell, a Cell Press publication. The newly discovered signaling molecule is the first example of a lipid-based hormone—most are made up of proteins--although the researchers said they expect it will not be the last.
Alternative Renewable Bio-Fuel Sources: Camelina Sativa and Switchgrass
INEOS Enterprises of the UK has entered into a partnership agreement with Great Plains-The Camelina Company for the purpose of expanding their bio-diesel enterprises world-wide. Great Plains-The Camelina Company is located in Montana and their achievements include establishing Camelina (oil seed) crushing machines and production facilities for creating bio-fuels. Switchgrass test plots at Auburn University have produced a five-year average of 11.5 tons of bio-mass equivalent to 1,150 gallons of ethanol per acre per year.
Nanomedical approach targets multiple cancer genes, shrinks tumors more effectively
Nanoparticles filled with a drug that targets two genes that trigger melanoma could offer a potential cure for this deadly disease, according to cancer researchers. The treatment, administered through an ultrasound device, demonstrates a safer and more effective way of targeting cancer-causing genes in cancer cells without harming normal tissue.

News discussion:

General Science news